Maverick Capital Ltd. Buys Shares of 9,472 CVS Health Corporation $CVS

Maverick Capital Ltd. purchased a new position in shares of CVS Health Corporation (NYSE:CVS) during the 1st quarter, Holdings Channel.com reports. The institutional investor purchased 9,472 shares of the pharmacy operator’s stock, valued at approximately $680,000.

Several other hedge funds have also recently bought and sold shares of the company. Norges Bank purchased a new stake in CVS Health during the fourth quarter worth $1,666,265,000. Wellington Management Group LLP increased its position in shares of CVS Health by 193.2% in the fourth quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock valued at $1,473,270,000 after buying an additional 12,233,675 shares in the last quarter. Amundi raised its stake in shares of CVS Health by 95.3% during the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock worth $572,665,000 after buying an additional 3,637,943 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of CVS Health by 44.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,219,756 shares of the pharmacy operator’s stock worth $446,703,000 after buying an additional 1,899,932 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of CVS Health by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after buying an additional 1,824,424 shares in the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS has recently outperformed the broader market, reflecting strong investor momentum following its earnings beat and improving outlook. CVS Health Laps the Stock Market
• Positive Sentiment: Analyst coverage remains broadly constructive, with CVS included among healthcare companies showing favorable indicators ahead of second-quarter 2026 results. Expectations for an earnings beat could support the stock, although execution and margins remain important. Zacks Analyst Blog Highlights CVS Health
• Positive Sentiment: CVS is again identified as one of four medical stocks positioned for a potential second-quarter earnings beat, supported by resilient demand for healthcare products and services. Medical Stocks With the Right Setup for Earnings Beats
• Positive Sentiment: Kate Farms is expanding distribution of its high-protein nutrition shakes into CVS stores, adding another health and wellness product that could modestly increase customer traffic and product breadth. Kate Farms Expands Distribution Into CVS
• Neutral Sentiment: Humana’s upcoming results are drawing attention to Medicare Advantage medical costs and guidance. A favorable report could reinforce sentiment toward health insurers, while cost pressure could have the opposite effect for CVS. Humana Earnings Face High Expectations
• Neutral Sentiment: CVS also highlighted community investments in Massachusetts, caregiving initiatives and recognition for supply-chain work. These support the company’s reputation but are unlikely to materially change near-term earnings. CVS Health Helping Strengthen Communities

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CVS. Cantor Fitzgerald lifted their target price on shares of CVS Health from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 7th. Bank of America raised their price objective on shares of CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Morgan Stanley lifted their price objective on CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a research report on Thursday, June 4th. Weiss Ratings upgraded CVS Health from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, July 20th. Finally, Royal Bank Of Canada raised their price target on CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a research report on Thursday, July 9th. Twenty-one investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and a consensus price target of $105.67.

CVS Health Stock Performance

Shares of CVS opened at $109.41 on Wednesday. CVS Health Corporation has a 1 year low of $58.99 and a 1 year high of $110.68. The company’s 50 day simple moving average is $100.73 and its 200 day simple moving average is $86.56. The company has a market capitalization of $139.59 billion, a price-to-earnings ratio of 48.20, a PEG ratio of 1.05 and a beta of 0.61. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The company had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, sell-side analysts predict that CVS Health Corporation will post 7.46 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd will be given a $0.665 dividend. The ex-dividend date of this dividend is Thursday, July 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.4%. CVS Health’s dividend payout ratio is presently 117.18%.

Insiders Place Their Bets

In related news, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the transaction, the director owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 3,441,551 shares of company stock worth $323,703,977. Insiders own 0.85% of the company’s stock.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.